Form 4 for GILD Gilead Sciences
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-10 · accession 0001127602-24-009540 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-11 | 2024-03-10 | GILD | Dickinson Andrew D | CFO | M - OptEx | — | +9,732 | 139.5K | +8% | — |
| D | 2024-03-11 | 2024-03-10 | GILD | Dickinson Andrew D | CFO | F - Tax | $75.12 | -4,505 | 135.0K | -3% | -$338.4K |
| DM | 2024-03-11 | 2024-03-10 | GILD | Dickinson Andrew D | CFO | M - OptEx | — | -9,732 | 28.3K | -26% | — |
| DM | 2024-03-11 | 2024-03-10 | GILD | Dickinson Andrew D | CFO | A - Grant | $0.00 | +105.3K | 88.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-10 | M | A | 3,025 | — | 132,781 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-03-10 | F | D | 4,505 | $75.12 | 134,983 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-10 | M | A | 6,707 | — | 139,488 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 4 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 3,025 | — | 35,040 | D | — · — to — | 3,025 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
| 5 | Derivative | Restricted Stock Unit | 2024-03-10 | A | A | 17,305 | — | 46,407 | D | — · — to — | 17,305 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F4) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-03-10 | A | A | 87,970 | $0.00 | 87,970 | D | $75.12 · — to 2034-03-10 | 87,970 Common Stock | (F5) The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 6,707 | — | 28,333 | D | — · — to — | 6,707 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F4) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |